Clofibrate hypocholesterolemia associated with increased hepatic copper

Area of Science:

• Biochemistry
• Cardiovascular Science
• Nutritional Science

Background:

• Copper metabolism plays a crucial role in cardiovascular health.
• Copper deficiency is hypothesized to be linked with hypercholesterolemia and ischemic heart disease.
• Clofibrate is known to affect lipid metabolism.

Purpose of the Study:

• To test the hypothesis that clofibrate's cholesterol-lowering effects are linked to copper metabolism.
• To investigate the relationship between copper deficiency, clofibrate administration, and cholesterol levels in rats.

Main Methods:

• Rats were fed a diet designed to induce copper deficiency.
• Clofibrate was administered as part of the copper-deficient diet.
• Blood plasma cholesterol and liver/plasma copper concentrations were measured.

Main Results:

• Rats treated with clofibrate exhibited significantly lower plasma cholesterol concentrations (20-29%).
• Copper-deficient rats receiving clofibrate showed increased liver copper (47-78%) and plasma copper (19-25%).
• These findings support the hypothesis that clofibrate influences cholesterol metabolism via copper metabolism.

Conclusions:

• Clofibrate demonstrates activity in copper-malnourished animals.
• The cholesterol-altering effects of clofibrate may be mediated by changes in copper metabolism.
• Clofibrate is identified as a cholesterotropic and cuprotropic chemical.